Categories: HealthcareNews

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya management will participate in the Piper Sandler 34th Annual Healthcare Conference, taking place in New York, NY, from November 29th to December 1st.

Details of Tenaya’s participation are as follows:

Panel Discussion: Heart to Heart with CV Players to Discuss 2023 Outlook
Date: November 29, 2022
Time: 2:30 – 3:25 p.m. ET

Fireside Chat
Date: November 30, 2022
Time: 8:30 – 8:55 a.m. ET

A webcast of the Piper Sandler event will be available by visiting the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Contacts
Investors
Michelle Corral
Vice President, Investor Relations and
Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com
  Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com

Staff

Recent Posts

Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship

The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…

23 minutes ago

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…

23 minutes ago

KLAS Report Shows Strong Early Results for TrustCommerce Cloud Payments

CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…

23 minutes ago

BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter

MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…

23 minutes ago

Truemed Closes $34 Million Series A To Unlock HSA/FSA Funds For Lifestyle Interventions

Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…

24 minutes ago

Trump’s Marijuana Schedule III Order Launches a Federally Regulated Healthcare Sector

MMJ's position is further fortified by its FDA Orphan Drug Designations for the treatment of…

24 minutes ago